Home / Intelligence / Blog / Developing Effective Global Value Dossiers
Published June 13, 2024
Trinity Life Sciences recently worked with a large global pharma company to develop a new process for creating global value dossiers (GVDs) that better met the needs of regional affiliates. Matt O’Hara, who leads Trinity’s Evidence Strategy practice, shares insights into the project with Mary Fletcher-Louis, who recently joined Trinity to head Trinity’s Value Center of Excellence.
Understanding the Challenge
The project involved reviewing the client’s 15 most recent GVDs and scoring each chapter for effectiveness, ease of use, level of detail and more. Regional affiliates were also interviewed to understand what they liked and what they found challenging about the GVDs.
Identifying Key Areas for Improvement
The team discovered that while the mechanics of GVD creation were usually well done, affiliates struggled to find the regional data most relevant to them and GVDs did not always help users see the strategic thread between different sections.
Developing a GVD Best Practice Toolkit
To address these challenges, Trinity developed a GVD best practice toolkit that provided guidance on how to write each chapter of the GVD. The toolkit also included several checklists and practical tools. These included a schematic showing what each stakeholder in the cross-functional team was responsible for and by when, as well as a mapping of drivers and evidence requirements for each country and checklists for each stage of the process.
Overcoming Challenges in GVD Development
Our analysis of GVDs across many therapy areas found that one challenge that teams frequently encounter is presenting a cogent economic story that aligns with the overall strategic goals of the GVD while also being practical and tactical.
The process developed by Trinity was designed to flex to different needs in different markets while maintaining consistency in how evidence is portrayed and messaged.
Conclusion and Call to Action
Overall, the project demonstrated the value of taking an independent view of GVD development and incorporating feedback from regional affiliates to create a more effective and streamlined process. If your company needs help with GVD development, Trinity’s Value Center of Excellence can provide guidance and support. Contact us to learn more.
Meet Our Experts
Related Intelligence
Webinars
Part D in Peril: The Inconvenient Math of IRA Part D Redesign
August 14, 2025 | 12:00 – 12:45 PM ET
Medicare Part D is undergoing its most significant transformation in decades largely driven by the IRA. What does this mean for pharmaceutical manufacturers? Join us for an engaging discussion with Max Hunt, Partner at Trinity, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage.
Sign Up Now
Blog
Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to […]
Read More
Blog
Pricing and Access in Germany: Innovation and Strong Evidence Rewarded
Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of […]
Read More